Modic Changes on Your MRI: Infection, Injury or Terrain?

The radiology paper that named the lesion studied six vertebrae under a microscope. The type 1 specimens showed fissured endplates and vascularized scar tissue; the type 2 specimens showed fatty marrow replacing red. There was no microbiology anywhere in it.

Decades later, people with Modic changes on an MRI are sometimes told they have a disc infection and handed three months of antibiotics. The video for Chapter 11 of The Angry Gut, by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, follows a patient through it. This article follows the measurements instead: what the finding is, what the lab work can and cannot tell you, and what repairs the terrain around a tired disc.

What Modic changes are

In that original series of four hundred and seventy-four consecutive lumbar scans, type 1 changes appeared in 4% and type 2 in 16%, always at a level with a degenerating disc. Over follow-up, five of six type 1 lesions converted to type 2. A modern synthesis treats the types as interconvertible stages of one process involving inflammation, fast bone turnover and fibrosis, with pain likely coming from nerve endings beside a damaged endplate.

How much does the finding matter? It appears in about 6% of people without back pain and a median of 43% of people with it. In an imaging meta-analysis of adults aged 50 or younger, type 1 carried an odds ratio of 4.01 for back pain, while an unspecified Modic change carried 1.62 with an interval crossing one.

The culture plate misled everyone

The infection idea started with surgeons culturing disc fragments and growing Cutibacterium acnes, a skin bacterium. The control data tell a different story. In a trial of 812 samples with purpose-built contaminant controls, non-degenerate trauma discs were positive more often, 48%, than degenerate discs at 27% and 17%, and positivity had no relationship to Modic changes.

Other designs found the same shape. A newer series found cervical samples positive in 25.71% of cases against 4.76% elsewhere, tracking sebaceous gland density on the upper back and neck rather than disease. A Swedish multicenter study found no bacterial DNA in 235 of 240 disc and vertebral samples. And a systematic review counted only 12 of 34 investigations that cultured the neighboring tissue as a control. Positivity followed the skin and the method, not the lesion.

The colonization case is not empty: one group saw a biofilm inside eight culture-positive discs, a pattern contamination does not build. Eight specimens, no comparison group.

Sequencing changed the question, then argued with itself

A culture plate only grows what tolerates a plate. When discs were sequenced, C. acnes ranked sixteenth by abundance in normal discs, at 0.72%, and seventh in Modic discs, at 1.41%. Bacterial DNA appeared in essentially every disc, including organ-donor discs, and in Modic discs gram-negative organisms made up more than half of what was found, the reverse of skin.

Then a Swiss group sequenced 70 discs and compared results with that earlier work. Using the same analysis settings, the two studies shared no bacterial genera. One software choice produced 48 genera or 22. Raising a filter cutoff from 4% to 50% took 48 genera down to 4. Only two findings survived every setting in both labs: more gram-negative organisms and lower diversity in Modic discs.

That is the non-obvious lesson for anyone buying a microbiome test. In low-biomass tissue, the method can generate the list. A census is not an activity report, and two censuses of the same lesion can disagree completely.

The endplate is a door

A disc has no blood supply. Oxygen and glucose diffuse in from vessels at its margins and through the endplate, and the center of the nucleus has the least oxygen, the least glucose and the most lactic acid. When the door narrows, through changes in the blood supply, hardening of the bone beneath or calcification of the endplate, disc cells die, less matrix is made and more is broken down. That is a route from a metabolic problem to a degenerating disc with no organism required.

The gut end of the road is a lower tier. In a pilot of 20 patients per subgroup, people with disc disease had fewer short-chain fatty acid producers in stool, and the Modic group showed depleted Bifidobacterium and Ruminococcus with enriched Streptococcus and Prevotella, while CRP ran high. No adjustment was reported for diet, body weight or painkillers. In mice, vesicles shed by a gut organism reached the disc and protected it; blocking the vesicles removed the protection. In the matching human stool cohort, age alone could explain much of the correlation.

No study has yet sequenced gut and disc from the same person. The practice works from mechanism, stated at that tier, because the patients most likely to have a leaky, inflamed gut are the ones trials screen out.

What the antibiotic evidence says now

A 2026 Cochrane review found three trials with 402 people. For type 1 changes with a disc herniation, pain on a 100-point scale was 8.42 points lower and disability 10.52 points lower on antibiotics, both at low certainty, and both measured at 12 to 14 weeks, the last day of the pills. An Australian trial published after that search randomized 170 people to the same drug and found a twelve-month pain difference of 0.06 on a 10-point scale, with adverse events in 40.0% against 23.5%. Only six of its participants had type 1 changes alone, so it did not test the original idea in the people it was about.

The honest summary: unproven, not disproven, with real harms. A pill reaches tissue through blood, and the disc is where blood does not go.

Measuring and repairing the terrain

Know your Modic type and whether you have a herniation. Track CRP across years, not a single week. If you have had surgery, ask whether the tissue next to the disc was cultured too. And notice whether your pain improves with movement, which points toward inflammation rather than mechanics.

Repair works on the door and the barrier together. Two biological drivers dominate: the vessels and bone at the endplate, whose narrowing starves the disc, and a gut barrier that decides what reaches the blood. One behavioral driver ties them: a diet of acellular carbohydrates and industrial seed oils that starves short-chain fatty acid producers and feeds metaflammation. The pumping action of walking does almost nothing to push nutrients into a disc, so movement earns its place through the metabolic health of the tissue around it, not by squeezing food inward.

Regenerative procedures fit into that terrain, not in place of it, as described in our intradiscal PRP protocol and why degeneration is not only mechanical. If your scan looks unremarkable and you still hurt, read your scan came back clean. The chapter before this, on what a vitamin D test misses, covers another number bent by the gut, and the next, on how far gut inflammation travels, follows it to the brain. Every study here is laid out with its limits in the Chapter 11 Deep Dive.

Frequently asked questions

Are Modic changes serious?

They are a marker of a stressed endplate, not a diagnosis on their own. About 6% of people without back pain have them, and type 1 is more strongly linked to pain than type 2. What matters is the type, the pain pattern and the metabolic and inflammatory terrain around the disc. How we approach chronic spinal pain as a whole system is outlined on our chronic back pain page.

Can Modic type 1 turn into type 2?

Yes. In the original series that defined the lesion, five of six type 1 changes converted to type 2 over roughly fourteen months to three years, while type 2 lesions stayed stable. Modern reviews treat the types as stages of one process involving inflammation, bone turnover and fibrosis. The same reviews compare them with bone marrow lesions in arthritic knees, which we explain in subchondral bone marrow lesions on knee MRI.

Are there bacteria in spinal discs?

Sequencing studies find bacterial DNA in most discs, including discs from organ donors with normal scans, so the old idea of a sterile disc is gone. Whether those bacteria cause pain is another matter. Culture positivity tracks skin contamination and surgical approach, and two labs sequencing Modic discs produced lists with no shared genera. The gut barrier that may let bacteria and their signals into circulation is covered in the leaky gut wall.

Can a stool test show whether my gut is affecting my spine?

Not reliably. Small pilot studies found fewer short-chain fatty acid producers in people with disc disease, but they did not adjust for diet, weight or medication, and genetic studies of gut taxa have not replicated. A stool test lists who is present, not what they are doing. Inflammation markers tracked over time tell you more. Why a microbial census fails to replicate is explained in the alcohol you never drank.

Do antibiotics work for Modic changes?

The pooled evidence shows a small, low-certainty benefit only for type 1 changes with a disc herniation, measured when the pills ended. A later twelve-month trial found no pain benefit and more adverse events, though few of its participants had type 1 changes. Antibiotics barely reach a disc with no blood supply. If a herniation is part of your picture, consider the options in herniated disc surgery alternatives.

Sources

1. Modic, M. T., Steinberg, P. M., Ross, J. S., Masaryk, T. J., & Carter, J. R. (1988). Degenerative disk disease: assessment of changes in vertebral body marrow with MR imaging. Radiology, 166(1 Pt 1), 193-9. https://doi.org/10.1148/radiology.166.1.3336678
2. Jensen, T. S., Karppinen, J., Sorensen, J. S., Niinimäki, J., & Leboeuf-Yde, C. (2008). Vertebral endplate signal changes (Modic change): a systematic literature review of prevalence and association with non-specific low back pain. European Spine Journal, 17(11), 1407–1422. https://doi.org/10.1007/s00586-008-0770-2
3. Brinjikji, W., Diehn, F. E., Jarvik, J. G., Carr, C. M., Kallmes, D. F., Murad, M. H., & Luetmer, P. H. (2015). MRI findings of disc degeneration are more prevalent in adults with low back pain than in asymptomatic controls: A systematic review and meta-analysis. AJNR. American Journal of Neuroradiology, 36(12), 2394–2399. https://doi.org/10.3174/ajnr.A4498
4. Rao, P. J., Maharaj, M., Chau, C., Taylor, P., Phan, K., Choy, W. J., Scherman, D., Mews, P., Scholsem, M., Coughlan, M., & Mobbs, R. (2020). Degenerate-disc infection study with contaminant control (DISC): A multicenter prospective case-control trial. The Spine Journal, 20(10), 1544–1553. https://doi.org/10.1016/j.spinee.2020.03.013
5. Granville Smith, I., Danckert, N. P., Freidin, M. B., Wells, P., Marchesi, J. R., & Williams, F. M. K. (2022). Evidence for infection in intervertebral disc degeneration: A systematic review. European Spine Journal, 31(2), 414-430. https://doi.org/10.1007/s00586-021-07062-1
6. Rajasekaran, S., Vasudevan, G., Easwaran, M., Devi Ps, N., Anand K S, S. V., Murugan, C., Shetty, A. P., Kanna, R. M., & Tangavel, C. (2023). “Are we barking up the wrong tree? Too much emphasis on Cutibacterium acnes and ignoring other pathogens” – a study based on next-generation sequencing of normal and diseased discs. The Spine Journal, 23(10), 1414–1426. https://doi.org/10.1016/j.spinee.2023.06.396
7. Mengis, T., Zajac, N., Bernhard, L., Heggli, I., Herger, N., Devan, J., Marcus, R., Brunner, F., Laux, C., Farshad, M., Distler, O., & Dudli, S. (2024). Intervertebral disc microbiome in Modic changes: lack of result replication underscores the need for a consensus in low-biomass microbiome analysis. JOR Spine, 7(2), e1330. https://doi.org/10.1002/jsp2.1330
8. Urban, J. P. G., Smith, S., & Fairbank, J. C. T. (2004). Nutrition of the intervertebral disc. Spine, 29(23), 2700-2709. https://doi.org/10.1097/01.brs.0000146499.97948.52
9. Liu, C., Abdel Shaheed, C., Braten, L. C., Hancock, M. J., Underwood, M., Jarvik, J. G., Elliott, J., Maher, C. G., Zhao, S., Lyu, M., Johnston, R. V., Buchbinder, R., & Lin, C. C. (2026). Antibiotic treatment for low back pain, radicular pain, or both. Cochrane Database of Systematic Reviews, 4(4), CD014221. https://doi.org/10.1002/14651858.CD014221.pub2
10. Cicuttini, F. M., Wluka, A. E., Pan, F., O’Sullivan, R., Leder, K., Cheng, A. C., & Urquhart, D. M. (2026). Efficacy of antibiotics for chronic low back pain with disc herniation: a randomized clinical trial. JAMA Network Open, 9(5), e2612848. https://doi.org/10.1001/jamanetworkopen.2026.12848

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, board certified in anesthesiology, pain medicine, interventional pain management, addiction medicine and obesity medicine. Adapted from Chapter 11 of The Angry Gut by Dr. Padda and Ami Michelle Grimes. Last reviewed September 2026.